Alert

Clinical Trial Details Page

LCCC 1317

Objective

Genotype-Directed Phase II Study of Higher Dose of Irinotecan in First-Line Metastatic Colorectal Cancer Patients Treated with Folfiri Plus Bevacizumab.

IRB Protocol Number
NCT02138617

Clinical Trial Categories

  • Colorectal
Contact
Nancy Burns at 919-784-7209
or Nancy.Burns2@unchealth.unc.edu
How to Participate

View eligibility criteria and additional study information.

Related Locations

Top